Piritrexim

General information

Piritrexim is a lipid-soluble analogue of methotrexate that has been used to treat methotrexate-resistant tumors [ ], including recurrent and metastatic head and neck cancers [ ], soft-tissue sarcomas [ ], non-small cell lung cancers [ ], metastatic melanoma [ ], urothelial cancers [ ], breast cancer [ ], gliomas [ ], and mycosis fungoides [ ]. It has also been used in psoriasis [ , ].

The major dose-limiting adverse reactions are myelosuppression [ ] and mucositis [ ]. Piritrexim is given with leucovorin (folinic acid) to minimize hematological toxicity [ ].

Drug studies